Abstract 1219P
Background
Prognostic markers in routine clinical practice of breast cancer are often assessed using RNA based multi-gene panels that are depending on a fluctuating tumor purity. Multiplex fluorescence immunohistochemistry (mfIHC) holds the potential for improved risk assessment.
Methods
To enable automated prognosis marker quantification, we have developed and validated a framework for automated breast cancer detection involving three different artificial intelligence analysis steps and an algorithm for cell-distance analysis using BLEACH&STAIN multiplex fluorescence immunohistochemistry. Pan-cytokeratin (panCK) antibodies were used to detect epithelial cells and antibodies directed against Myosin and p63 were used to identify basal cells.
Results
The optimal distance between Myosin+ and p63+ basal cells and benign panCK+ cells was identified as 25 μm in breast cancer and used – combined with deep learning-based algorithms – to exclude benign glands from the analysis. Our framework discriminated normal glands from malignant glands with an accuracy of 98.4% (95% confidence interval [CI]: 97.4 – 99.3). The approach for automated breast cancer detection improved the predictive performance of several prognosis markers significantly (each p<0.05) and a comparison with manually assessed data using conventional brightfield immunohistochemistry showed a high concordance for a multitude of different prognosis marker such as PR, ER, GATA3, HER2, and PD-L1 (each p<0.0001).
Conclusions
The combined assessment of up to 5 markers in a prognosis score showed strong prognostic relevance (p<0.001) and was an independent risk factor in multivariate analysis (p=0.005). Thus, the data from this study show that automated breast cancer detection in combination with artificial intelligence-based analysis of multiplex fluorescence immunohistochemistry enables a rapid and reliable analysis of multiple prognostic parameters. The major advantage of this method is the analysis of malignant cells exclusively that cannot be achieved using RNA-based panel analysis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
G. Sauter: Other, Personal, Other, The GATA3 (MSVA-450M), PD-L1 (MSVA-711R), PR (MSVA-570R), AR (MSVA-367R), ER (MSVA-564R), TROP2 (MSVA-733R), TOP2A (MSVA-802R), Myosin (MSVA-375R), panCK (MSVA-000R), Ki-67 (MSVA-267M) antibodies were provided by MS Validated Antibodies GmbH (owned by a family member of GS): MSVA. All other authors have declared no conflicts of interest.
Resources from the same session
1794P - Prognostic role of metastatic site in patients with de novo metastatic prostate cancer: A population-based analysis in new hormonal agents era
Presenter: Emre Yekeduz
Session: Poster session 14
1795P - China ARCHES: A multicenter phase III randomized double-blind placebo (PBO)-controlled efficacy and safety trial of enzalutamide (ENZA) + androgen deprivation therapy (ADT) vs PBO + ADT in Chinese patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC)
Presenter: Gongqian Zeng
Session: Poster session 14
1796P - Real-world analysis of metastatic hormone-sensitive prostate cancer: Are randomized clinical trials more trustworthy? Insights from PIONEER, the European network of excellence for big data in prostate cancer
Presenter: Juan Gómez Rivas
Session: Poster session 14
1797P - Application of novel machine learning model in [68Ga] Ga-PSMA-11 PET/CT: Predicting survival in oligometastatic prostate cancer patients
Presenter: Mikaela Dell'Oro
Session: Poster session 14
1800P - Differential tumor gene-expression profiling of patients (pts) with de-novo metastatic castration-sensitive prostate cancer (dn-mCSPC) versus (vs.) mCSPC relapsing after prior localized therapy (PLT-mCSPC)
Presenter: Vinay Mathew Thomas
Session: Poster session 14
1803P - Phase I/II study of bavdegalutamide, a PROTAC androgen receptor (AR) degrader in metastatic castration-resistant prostate cancer (mCRPC): Radiographic progression-free survival (rPFS) in patients (pts) with <italic>AR</italic> ligand-binding domain (LBD) mutations
Presenter: Daniel Petrylak
Session: Poster session 14